TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with PsA for at least 6 months before screening, and who meet the Classification Criteria for Psoriatic Arthritis (CASPAR) at screening~* Participants either (i) cannot have prior exposure to biologics (biologic-naïve) or (ii) have failed or been intolerant to 1 tumor necrosis factor -inhibitor (TNFi) (TNFi-experienced). Failure is defined as lack of response or loss of response with at least 3 months of therapy with an approved dose of a TNFi, as judged by the investigator. Failure must have occurred at least 2 months prior to Day 1~* Participants have at least 1 confirmed greater than or equal to (\>=) 2 centimeter (cm) lesion of plaque psoriasis at screening~* Participants have active arthritis as shown by a minimum of \>= 3 swollen joints and \>= 3 tender joints (66/68 joint counts) at screening and Day 1~* High sensitivity C-reactive protein (hsCRP) \>= 3milligram per liter (mg/L) at screening~* Women of Childbearing Potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment~Exclusion Criteria:~* Has non-plaque psoriasis (that is (i.e.), guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at screening or Day 1~* Has any other autoimmune condition such as rheumatoid arthritis, etc. There are exceptions for inflammatory bowel disease or uveitis as follows: currently active disease is excluded but, a history of no longer active disease for at least 12 months (including not being on medication) is allowed~* Has active (i.e. currently symptomatic) fibromyalgia~* History or evidence of active infection and/or febrile illness within 7 days prior to Day 1 (example, bronchopulmonary, urinary, gastrointestinal, etc.)~* History of recent serious bacterial, fungal, or viral infections requiring hospitalization and intravenous (IV) antimicrobial treatment within 90 days prior to screening, or any infection requiring antimicrobial treatment within 15 days prior to Day 1~* History of active tuberculosis (TB) prior to screening visit, regardless of completion of adequate treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: Placebo (Type: PLACEBO_COMPARATOR): None
- Part A: BMS-986165 Dose A (Type: EXPERIMENTAL): None
- Part A: BMS-986165 Dose B (Type: EXPERIMENTAL): None
- Part B: Ustekinumab + BMS-986165 Placebo (Type: EXPERIMENTAL): None
- Part B: BMS-986165 Dose A + Ustekinumab Placebo (Type: EXPERIMENTAL): None
- Part B: BMS-986165 Dose B + Ustekinumab Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Oral Sedation-related Events of Three Multiagent Oral Sedation Regimens in Pediatric Dental Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled to undergo oral sedation appointments in Loma Linda University Pediatric dental clinic for operative procedures.~* Age 3-7 years old, Healthy ( ASA-1 )~* No gender, race or ethnic restrictions.~* Reason for conscious oral sedation is situational anxiety in the dental operatory~Exclusion Criteria:~* Children with a history of acute illness~* History upper respiratory tract infection within two weeks of treatment~* Children taking any medication within the two weeks prior to scheduled dental treatment~* Sedation within the last six months~* Body mass index (BMI) greater than the 95th percentile for their age and sex~* Failing to drink the entire amount of sedation medications dispensed

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Regimen 1 (Type: ACTIVE_COMPARATOR): Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration - Meperidine (1.5 -2 mg/kg) Oral administration - Midazolam (0.5- 0.75 mg/kg) Inhalation - Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2)
- Regimen 2 (Type: EXPERIMENTAL): Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration- Meperidine (1.5 -2 mg/kg) Inhalation - Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) -
- Regimen 3 (Type: EXPERIMENTAL): Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration - Midazolam (0.5- 0.75 mg/kg) Inhalation- Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ScanBrit Dietary Intervention in Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Autism Spectrum Disorder (ASD)~* Diagnosis received at Centre for Autism or a psychiatric clinic~* Abnormal urinary peptide profile~Exclusion Criteria:~* Medical treatment~* Epilepsy

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Gluten- and casein-free diet (Type: EXPERIMENTAL): Stage 1: Gluten- and casein-free dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If showed group significant improvements then progressed to stage 2 (continued on a gluten- and casein-free diet for a further 12 months).
- No dietary intervention (Type: NO_INTERVENTION): Stage 1: No special dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If gluten- and casein-free dietary group showed group significant improvements then progressed to stage 2 (introduction of a gluten- and casein-free diet for 12 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Insulin dose of \>1.8 units/kg/day (represents total daily insulin dose, regardless of formulation, regimen, number of daily shots)~* HbA1c ≥ 7.5% and ≤ 11%~* Age ≥ 18~* Stable comorbidities on stable treatment regimens~* Stable dose of all oral hypoglycemics for ≥ 3 months prior to enrollment~* Ability to provide informed consent before any trial-related activities~Exclusion Criteria:~* Type 1 diabetes mellitus~* Any contraindication to the MRI procedure (metallic implants, severe claustrophobia, pregnancy, unable to lie still on a hard table for the duration of the procedure, weight above 400 lb - limit of the MRI table, magnet's inner circumference smaller than the largest body circumference)~* History of any pancreatic disease as it might interfere with the pancreatic TG measurement (i.e. pancreatitis, tumors, cysts, type 1 diabetes, any pancreatic surgery)~* End Stage Renal Disease on dialysis due to increased risk of hypoglycemia, and possible interference with accurate measurement of HbA1c~* Incretin therapy (any GLP-1 agonist or DPP-IV inhibitor)~* Unstable or decompensated comorbidities~* Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome~* Severe gastroparesis~* Pregnancy, breast feeding, intention to become pregnant, or not using adequate contraceptive measures~* Organ transplant recipient or waiting list candidate~* Steroid use (current or potential use during the trial)~* Known/suspected allergy to trial medication, excipients, or related products~* Contraindications to study medications, worded specifically as stated in the product's prescribing information~* Non-English speaking volunteers since no interpreters are available and the safety of the volunteers could be jeopardized if adequate and reliable communication is not possible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: ACTIVE_COMPARATOR): None
- Saline injection (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants in good general health, with self-reported history of dentinal hypersensitivity lasting more than 6 months but not more than 10 years.~* Participants with minimum of 20 natural teeth.~* At screening, a minimum of four, non-adjacent teeth.~  1. Teeth showing signs of facial/cervical gingival recession and/or signs of erosion or abrasion.~ 2. Teeth with Gingival Index score ≤1 and a clinical mobility of ≤1.~ 3. Teeth that are determined to be sensitive by the participant following a 1 second air blast to the cervical margin.~Exclusion Criteria:~* Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes.~* Any condition which, in the opinion of the investigator, causes dry mouth.~* Tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of screening.~* In the 8 weeks prior to screening use of an oral care product indicated for the relief of DH.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Potassium nitrate and sodium fluoride (Type: EXPERIMENTAL): 3.0% weight by weight (w/w) potassium nitrate mouthwash with 0.02% sodium fluoride
- Standard fluoride dentifrice (Type: OTHER): Standard fluoride dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate (SMFP)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elderly patients (age ≥60 years);~* Scheduled to undergo elective major non-cardiac surgery with expected duration ≥2 hours under general anaesthesia.~Exclusion Criteria:~* Do not provide written informed consent;~* Previous history of schizophrenia, epilepsy or Parkinson's disease;~* Visual, hearing, language or other barriers which impede communication and preoperative delirium assessment;~* History of traumatic brain injury;~* Severe bradycardia (heart rate \<40 beats per minutes), sick sinus syndrome, or atrioventricular block of degree 2 or above without pacemaker;~* Severe hepatic dysfunction (Child-Pugh grade C);~* Renal failure (requirement of renal replacement therapy);~* Neurosurgery.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
- Control group (Type: PLACEBO_COMPARATOR): Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Training and Practice Effects in Mild Cognitive Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild Cognitive Impairment, amnestic subtype~  * 65 years of age or older~ * Availability of a knowledgeable informant~* Access to internet 3 hours per week~* Adequate vision, hearing, and motor responding to participate in training~Exclusion Criteria:~* History of major stroke, head injury with loss of consciousness of \>30 minutes, or other neurological disorder or systemic illness that are thought to be affecting cognition (e.g., seizure disorder, demyelinating disorder, etc.)~* Current or past major psychiatric illness (e.g., schizophrenia, bipolar affective disorder)~* History of substance abuse~* Current use of antipsychotics or anticonvulsant medications~* Currently residing in a nursing home or other skilled nursing facility

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- experimental cognitive training (Type: EXPERIMENTAL): Participants will use experimental computerized cognitive training exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks.
- control cognitive exercises (Type: ACTIVE_COMPARATOR): Participants will use control computerized cognitive activities, 1 hour per day, 3 - 5 days per week, for 13 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Alzheimer's disease according to the criteria of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)~* Measuring standard: K-MMSE is 10 to 24~* Patient with reliable Guardian~Exclusion Criteria:~* Patients with brain tumor, nerve syphilis, meningitis, encephalitis, epilepsy~* Major psychiatric patients such as major depression and schizophrenia~* Patients with treatment-resistant gastric and peptic ulcer~* Patients with clinically serious hepatic, renal, lung, endocrinal or metabolic disease (thyroid, parathyroid, pituitary, renal failure, diabetes mellitus)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Galantamine (Type: None): Patients will receive galantamine 8 mg/day for the first 4 weeks and the dose of galantamine will be increased up to 24 mg (if tolerable).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Wearable Monitoring Systems for Swallowing Function and Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria for healthy adults:~* Age 18-30 OR 50-90 years of age~* No history of dysphagia~* No history of a neurological disorder~* A score in the normal/mild range on the Montreal Cognitive Assessment (MoCA):~* A score of \<3 on the Eating Assessment Tool-10 (EAT-10, a self-report screening for dysphagia).~Inclusion criteria for patients with dysphagia:~* Age 18-90 years of age~* Diagnoses of dysphagia as a result of a neurological disorder (e.g., stroke, Parkinson's disease).~* A score in the normal/mild range on the Montreal Cognitive Assessment (MoCA).~* A score of ≥3 on the Eating Assessment Tool-10 (EAT-10, a self-report screening for dysphagia).~Exclusion Criteria:~• Significant cognitive impairment (a score in the moderate-severe range on MoCA):

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Group A: Conventional Sensors First, Then Experimental (Tele-EaT) Sensors (Type: OTHER): Group A participants will complete the experimental protocol (swallow trials) with the conventional (commercially available) electrodes/sensors first. After a break of 10 minutes, they then will repeat the exact same experimental protocol (exact same swallow trials) with the experimental sensors (i.e., a wearable surface EMG sensors patch we are developing).
- Group B: Experimental (Tele-EaT) Sensors First, Then Conventional Sensors (Type: OTHER): Group B participants will complete the experimental protocol (swallow trials) with the experimental sensors (i.e., a wearable surface EMG sensors patch we are developing) first. After a break of 10 minutes, they then will repeat the exact same experimental protocol (exact same swallow trials) with the conventional (commercially available) electrodes/sensors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Oxygen for Gastrointestinal Atony (TOGA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patient or health proxy has been adequately informed of risks and benefits and agrees to his/her participation in the study.~* patient is a hospitalized inpatient diagnosed with ileus, bowel obstruction or colonic pseudo-obstruction \[clinician interpretation or small bowel diameter ≥3.5 cm, cecal diameter ≥ 9 cm, sigmoid colon diameter ≥ 6 cm\].~* patient is clinically and hemodynamically stable~* patient does not require supplemental oxygen greater than 2 liters per minute via nasal cannula~* patient does not have any respiratory contraindications to 100% oxygen~* failure to respond to non-surgical/non-endoscopic therapy for at least 24 hours, therapy at discretion of treating physician \[to eliminate patients with trivial ileus not requiring advanced intervention\]~Exclusion Criteria:~* patient is not expected to survive in the short term.~* patient is a pregnant or lactating woman.~* patient presents with severe or unstable psychiatric disorders.~* patient is participating in concomitant research studies that would interfere with this study.~* patient is an alcohol or drug abuser.~* respirator support required.~* unable to tolerate 100% oxygen for respiratory reasons or any other reasons.~* perforation of the viscus.~* inability to obtain informed consent.~* hypoxemia, as in room air oxygen saturation less than 90%.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Hospitalized Ileus or Pseudo-Obstruction Patient (Type: EXPERIMENTAL): Hospitalized inpatient diagnosed with ileus, bowel obstruction or colonic pseudo-obstruction \[clinician interpretation or small bowel diameter ≥3.5 cm, cecal diameter ≥ 9 cm, sigmoid colon diameter ≥ 6 cm\] provided with 100% oxygen via non-rebreather face mask, for 6 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria included:~• Eyes with established diagnosis of NK in stages 2 or 3 refractory to standard treatment\* that underwent topical insulin treatment.~The diagnosis of NK was based on the following criteria:~1. Decreased or absence of corneal sensation; AND~2. Corneal injury \[PED and/or corneal ulcer\] refractory to standard treatment\*; AND~3. Clinical history of conditions related to trigeminal innervation impairment;~   * Standard treatment - lubrication with artificial tears, topical and/or oral antibiotics, topical and/or oral steroids, antiviral drugs, punctal plugs, therapeutic CL, amniotic membrane surgery and temporary tarsorrhaphy.´~We excluded every patient with corneal ulcer and signs of infection.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Therapy for Prevention of Infections in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants~Exclusion Criteria:~* Full-term infant

- Gender: ALL
- Minimum Age: 7 Months
- Maximum Age: 8 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete